Company Overview - Natera is a genetic testing company specializing in detecting tiny quantities of DNA across healthcare areas [3] - The company has a market cap of approximately $22 billion [2] - Natera has processed 12 million tests so far [11] Technology and Products - Natera's technology can detect cancer recurrence up to two years in advance of imaging [4][8] - The company utilizes a unique test called Signatera, specialized for each patient, to detect circulating tumor DNA [5][7] - The test sequences the entire tumor and compares it to the patient's germline DNA to identify unique signatures [7][9] Market and Financials - Natera operates in a total addressable market estimated at $50 billion [12] - The MRD (Minimal Residual Disease) segment, including Signatera, represents a $20 billion market [12] - The company follows standard billing and reimbursement guidelines and is in-network with most insurance plans [10][11]